Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.6277 USD | +3.41% | +2.07% | -53.50% |
Sales 2024 * | 3K 250K | Sales 2025 * | 2.5M 209M | Capitalization | 22.52M 1.88B |
---|---|---|---|---|---|
Net income 2024 * | -68M -5.67B | Net income 2025 * | -77M -6.42B | EV / Sales 2024 * | 7,508 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 9 x |
P/E ratio 2024 * |
-0.43
x | P/E ratio 2025 * |
-0.49
x | Employees | 58 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 106.9% |
Latest transcript on Biora Therapeutics, Inc.
1 day | +3.41% | ||
1 week | +2.07% | ||
Current month | -42.94% | ||
1 month | -46.35% | ||
3 months | -33.22% | ||
6 months | -67.81% | ||
Current year | -53.50% |
Managers | Title | Age | Since |
---|---|---|---|
Adi Mohanty
CEO | Chief Executive Officer | 57 | 08/21/08 |
Eric d'Esparbes
DFI | Director of Finance/CFO | 56 | 01/19/01 |
Ariella Kelman
CTO | Chief Tech/Sci/R&D Officer | - | 01/23/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 49 | 01/14/01 | |
Jeffrey Alter
CHM | Chairman | 61 | 01/19/01 |
Adi Mohanty
CEO | Chief Executive Officer | 57 | 08/21/08 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.00% | 2 M€ | -.--% |
Date | Price | Change | Volume |
---|---|---|---|
26/24/26 | 0.6277 | +3.41% | 133,686 |
25/24/25 | 0.607 | -2.08% | 151,521 |
24/24/24 | 0.6199 | -2.99% | 184,411 |
23/24/23 | 0.639 | +5.43% | 383,304 |
22/24/22 | 0.6061 | -1.45% | 160,218 |
Delayed Quote Nasdaq, April 27, 2024 at 01:30 am IST
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-53.50% | 22.52M | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.73B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- BIOR Stock